Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are highlighting the pill's trajectory as the defining question for the company's medium-term outlook following a strong set of first-quarter results and a London investor event.